Year: 2024

Bridging the primary care gap: The role of in-house pharmacies in today’s healthcare marketplace

April 4, 2024 Sponsored Content Views

Removing the Headache of Running an On-Site Pharmacy

340B Stakeholders Clash on Patient Definition, 340B Spending Requirements in Comments on Senate ‘Group of Six’ Draft Overhaul

April 4, 2024 William Newton, Associate Editor/Senior Writer Views

Advocacy groups for providers and drugmakers had diverging views in their comments on a draft Senate 340B overhaul.

Stakeholders disagreed on whether Congress should codify a new 340B patient definition or restrict how providers use 340B savings, in [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Hospitals Say HRSA Violated Federal Rulemaking in 340B Child Site Waiver Reversal

April 4, 2024 Rich Daly, Editor in Chief Views

More than 40 health systems told a federal district court that a HRSA hospital offsite clinic registration policy reversal violated federal rulemaking requirements.

The dozens of health systems suing the federal government over the reversal of a pandemic-era 340B child site registration waiver [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Genentech Officially Issues Contract Pharmacy Restrictions

April 4, 2024 Rich Daly, Editor in Chief Views

Pharmaceutical manufacturer Genentech has formally implemented 340B contract pharmacy restrictions for hospitals.

Drugmaker Genentech has formally issued contract pharmacy restrictions after it gave some 340B hospitals advance notice last month of its [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

AbbVie Adds Cancer Drug to Contract Pharmacy Restriction Policy

April 4, 2024 Shannon Young, Associate Editor/Senior Writer Views

Drug manufacturer AbbVie recently added a cancer medication to its 340B contract pharmacy restrictions for hospitals.

Drug manufacturer AbbVie is adding a cancer treatment to the list of drug products that only will be available to [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Contract Pharmacies Have Proliferated, Conservative Group Says, Citing Data from Pharma-Funded Think Tank

April 4, 2024 Rich Daly, Editor in Chief Views

A Paragon Health Institute analysis found the share of 340B contract pharmacies per covered entity has increased in recent years.

Active 340B contract pharmacies reached 17,250 in 2024, according to a conservative think tank using data collected by another group funded by [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Four More Drugmakers to End 340B Contract Pharmacy Restrictions in Arkansas Following Appeals Court Decision

April 2, 2024 William Newton, Associate Editor/Senior Writer Views

At least nine drugmakers have modified their contract pharmacy restrictions in Arkansas after the state said it planned to enforce its 340B law following an appeals court decision. An additional nine manufacturers loosened restrictions prior to the court decision.

Bristol Myers Squibb (BMS), Amgen, and Bayer became the latest drugmakers to formally exempt Arkansas providers from their 340B contract [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Sumitomo Is Thirty-Second Company to Implement Contract Pharmacy Restrictions

April 2, 2024 Rich Daly, Editor in Chief Views

Sumitomo is the 32nd pharmaceutical manufacturer to place restrictions on 340B drug shipment in the contract pharmacy setting.

Drugmaker Sumitomo Pharma America (SMPA) announced it will implement first-time contract pharmacy restrictions next month. The biotech company, which is [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Astellas Adds Second Drug to 340B Contract Pharmacy Restrictions

April 2, 2024 William Newton, Associate Editor/Senior Writer Views

Pharmaceutical manufacturer Astellas recently added a second medication to its 340B contract pharmacy restrictions.

Japanese drugmaker Astellas will soon extend its limits on 340B pricing to hospitals for its medication to treat overreactive bladder, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Site Footer Live